People who stop using the weight-loss injection Mounjaro (tirzepatide) tend not only to regain weight, but also lose key health benefits such as improved blood pressure, cholesterol and blood sugar levels, according to new research.
Data from the Surmount-4 clinical trial showed that among participants who had lost at least 10% of their body weight, 82% regained 25% or more of that weight within a year of stopping the drug. Those who regained the most weight also saw their blood pressure, “bad” cholesterol, waist size and glucose levels return close to pre-treatment levels.
Experts said the findings were expected, as excess weight drives many cardiometabolic risks. Professor Naveed Sattar of the University of Glasgow warned that stopping the medication may also remove protective effects against heart problems.
Researchers said the results highlight the need for long-term weight maintenance through lifestyle changes and, where appropriate, ongoing medication. Other experts noted that weight-loss jabs do not always lead to lasting healthy eating or exercise habits, which can make weight regain more likely once treatment stops.
Separate research suggested women who stop weight-loss drugs before or during early pregnancy may face higher risks of complications, though experts cautioned that more evidence is needed.
